The clinical trial for RZ-001, which uses a proprietary RNA trans-splicing ribozyme platform to target cancer cells, reports a manageable safety profile among its initial cohort. Analysis of the first 10 enrolled patients indicates no dose-limiting toxicity or Grade 4 adverse events, with most complications attributed to the underlying malignancy rather than the treatment itself. Several participants experienced tumor recurrence inhibition lasting beyond six months, a duration exceeding the typical two-to-four-month window for this aggressive brain cancer.

Dr. Kim emphasized that the data showing recurrence inhibition past nine months provides a promising signal for a condition that remains notoriously difficult to treat. Rznomics, which listed on the KOSDAQ last December, is currently expanding its clinical efforts. Beyond the glioblastoma study, the company is advancing an RZ-001 program for hepatocellular carcinoma, which secured Regenerative Medicine Advanced Therapy designation from the U.S. FDA in May 2026.